<DOC>
	<DOCNO>NCT00611247</DOCNO>
	<brief_summary>Open-label , non-randomized , parallel assignment , phase 2 trial assess safety efficacy distinct temozolomide treatment regimens patient AML poor prognosis</brief_summary>
	<brief_title>Phase 2 Study Temozolomide Treat Poor Risk / Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>This single institution phase 2 clinical trial evaluate efficacy , safety , tolerability tailor temozolomide therapy patient acute myeloid leukemia ( AML ) poor risk feature . Patients assign 1 2 parallel treatment group base AGAT promoter region methylation status , determine PCR . Patients achieve complete remission 1 2 cycle chemotherapy eligible receive additional 5 cycle temozolomide 5 19 day , depend methylation status AGAT promoter ( consolidation phase ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm Acute Myeloid Leukemia , define WHO classification . 2 . Patients must consider unfit conventional induction chemotherapy , unwilling receive treatment evidence disease relapse refractory disease . 3 . For patient receive prior conventional chemotherapy , one follow must present : Poor risk cytogenetics ( complex abnormality , deletion chromosome 7 5 , 11q23 abnormality , inv [ 3 ] ) Secondary leukemia ( prior hematologic disorder therapyrelated leukemia ) . 4 . Age &gt; 60 year age . 5 . Life expectancy great 3 month . 6 . ECOG performance status great 2 . 7 . Patients must normal organ marrow function define : 8 . Adequate hepatic function : Total bilirubin 1.5mg/dL , AST ( SGOT ) /ALT ( SGPT ) 2.5 X institutional upper limit normal . 9 . Adequate renal function : serum creatinine within normal institutional limit Calculated creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level institutional normal . 10 . Ability understand willingness sign write informed consent document . 1 . Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier . 2 . Patients may receive investigational agent . 3 . History allergic reaction attribute compound similar chemical biologic composition temozolomide DTIC 4 . History gastrointestinal disease significant bowel resection could interfere drug absorption . 5 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 6 . Prior allogeneic stem cell transplantation . 7 . Inability swallow tablet 8 . Prior radiation 25 % bone marrow .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>